Dianthus Therapeutics (DNTH) Stock: Buy, Sell, or Hold?
DNTH - Dianthus Therapeutics, Inc. Common Stock
$76.79
-1.31 (-1.68%)
▼
5d:
+3.03%
30d:
-17.82%
90d:
-26.07%
BUY
MODERATE Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 04, 2026
12d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Oct 20, 2026 at $78.34 · last confirmed Oct 21, 2026
Strength: 7.0/10
Get Alerted When DNTH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DNTH shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DNTH shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DNTH is currently trading at $76.79, which is considered slightly low relative to its 30-day fair value range of $78.74 to $98.63.
Technical Outlook: Technically, DNTH is showing sideways momentum. Immediate support is located at $69.43, while resistance sits at $85.20.
Market Sentiment: DNTH scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $140.80 (+80.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DNTH is showing sideways momentum. Immediate support is located at $69.43, while resistance sits at $85.20.
Market Sentiment: DNTH scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $140.80 (+80.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$78.74 -
$98.63
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 80.3% below Wall St target ($140.80)
- BULLISH: Bottoming setup score 68/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$78.74 -
$98.63
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$69.43
Resistance Level
$85.20
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-16.94
Wall Street Target
$140.80
(+80.3%)
Revenue Growth (YoY)
294.3%
Share & Embed Analysis
Last updated: October 22, 2026 1:57 PM ET
Data refreshes hourly during market hours. Next update: 2:57 PM
Data refreshes hourly during market hours. Next update: 2:57 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DNTH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 58 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 67 BUY |
|
NUVB
Nuvation Bio Inc |
STRONG BUY
13 analysts |
$13 | 77 BUY |
Advanced DNTH Option Strategies
Professional options setups generated by AI based on today's DNTH price and gamma walls.
